Bristol Myers just deployed the most powerful AI supercomputer in life sciences

Bristol Myers Squibb just deployed Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems.

The most powerful single-owned AI infrastructure in life sciences.

10x performance per megawatt vs the previous generation.

55% cost reduction on AI workloads from the last system.

This isn't a pharma story. It's an infrastructure story.

BMS isn't renting cloud AI. They're building their own AI factory.

Because drug discovery is too important to share compute with everyone else.

They get access to Nvidia's BioNeMo platform and Agent Toolkit.

Autonomous AI agents that run drug discovery tasks with minimal human involvement.

The pattern is clear: Eli Lilly did it. Amgen built one in Iceland. Roche launched a hybrid-cloud AI factory.

The enterprises winning the AI race aren't just buying models. They're building dedicated infrastructure that competitors can't access.

Audit your AI infrastructure strategy today.

If you're still relying entirely on shared cloud services, you're trading performance for convenience.

The companies building their own AI factories will have a structural advantage that compounds over time.